1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Jon Pilcher from Neuren Pharmaceuticals (ASX:NEU) shares optimism as the company celebrates a US patent for its Pitt Hopkins syndrome treatment, securing market protection until 2040. Neuren is also eyeing a promising future for its Rett syndrome treatment, debuting with Acadia Pharmaceuticals.
The debut, approved by the US FDA, is a commercial success, generating significant revenue and poised for growth in Europe and Japan. Jon highlights that only a third of Rett syndrome patients in the US have tried the treatment, with a robust plan to expand sales further.
Neuren's strong financial position, bolstered by $300 million in cash, enables it to advance its pipeline, including the upcoming phase three trial for Phelan-McDermid Syndrome syndrome. Jon notes the team's readiness to initiate this landmark trial mid-year.
